SHANGHAI – Singapore-headquartered Aslan Pharmaceuticals Pte Ltd. is deepening its ties to Taiwan. The oncology-focused biopharma has been growing its operational presence in Taiwan over the last three years, and is now making moves to go public there in 2017. In preparation, Aslan took on $23 million in series D financing from a group of local and global investors.